Orchestra BioMed Hldgs Analyst Ratings
Orchestra BioMed Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 261.01% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 05/15/2023 | 261.01% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 02/24/2023 | 170.76% | Piper Sandler | → $15 | Initiates Coverage On | → Overweight |
| 02/07/2023 | 261.01% | Chardan Capital | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/09/2023 | 261.01% | 查丹资本 | → 20 美元 | 重申 | 购买 → 购买 |
| 05/15/2023 | 261.01% | 查丹资本 | → 20 美元 | 重申 | 购买 → 购买 |
| 02/24/2023 | 170.76% | 派珀·桑德勒 | → 15 美元 | 启动覆盖开启 | → 超重 |
| 02/07/2023 | 261.01% | 查丹资本 | → 20 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Orchestra BioMed Hldgs (OBIO)?
Orchestra BioMed Hldgs（OBIO）的目标价格是多少？
The latest price target for Orchestra BioMed Hldgs (NASDAQ: OBIO) was reported by Chardan Capital on August 9, 2023. The analyst firm set a price target for $20.00 expecting OBIO to rise to within 12 months (a possible 261.01% upside). 4 analyst firms have reported ratings in the last year.
Chardan Capital于2023年8月9日公布了Orchestra BioMed Hldgs（纳斯达克股票代码：OBIO）的最新目标股价。这家分析公司将目标股价定为20.00美元，预计OBIO将在12个月内升至20.00美元（可能上涨261.01％）。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Orchestra BioMed Hldgs (OBIO)?
Orchestra BioMed Hldgs（OBIO）的最新分析师评级是多少？
The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ: OBIO) was provided by Chardan Capital, and Orchestra BioMed Hldgs reiterated their buy rating.
Orchestra BioMed Hldgs（纳斯达克股票代码：OBIO）的最新分析师评级由Chardan Capital提供，Orchestra BioMed Hldgs重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Orchestra BioMed Hldgs (OBIO)?
Orchestra BioMed Hldgs（OBIO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Orchestra BioMed Hldgs的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Orchestra BioMed Hldgs的最后评级是在2023年8月9日提交的，因此你应该预计下一个评级将在2024年8月9日左右公布。
Is the Analyst Rating Orchestra BioMed Hldgs (OBIO) correct?
分析师评级 Orchestra BioMed Hldgs (OBIO) 正确吗？
While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a reiterated with a price target of $0.00 to $20.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $5.54, which is within the analyst's predicted range.
尽管收视率是主观的，将会发生变化，但最新的Orchestra BioMed Hldgs（OBIO）评级得到了重申，目标股价为0.00美元至20.00美元。Orchestra BioMed Hldgs（OBIO）目前的交易价格为5.54美元，在分析师的预测区间内。